VIP is reported as an anti-inflammatory and immune-modulatory peptide that has considered being a potential candidate for treatment of inflammatory and autoimmune diseases through down-regulation of inflammatory cytokines and mediators. This evidence concerns the gene VIP and autoimmune disease.